Free Trial

Bristol-Myers Squibb (BMY) Stock Price, News & Analysis

-0.75 (-1.82%)
(As of 05/28/2024 ET)
Today's Range
50-Day Range
52-Week Range
14.53 million shs
Average Volume
15.52 million shs
Market Capitalization
$82.08 billion
P/E Ratio
Dividend Yield
Price Target

Bristol-Myers Squibb MarketRank™ Stock Analysis

Analyst Rating
2.11 Rating Score
48.2% Upside
$60.00 Price Target
Short Interest
1.39% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.54mentions of Bristol-Myers Squibb in the last 14 days
Based on 37 Articles This Week
Insider Trading
Proj. Earnings Growth
From $0.59 to $7.05 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.96 out of 5 stars

Medical Sector

3rd out of 931 stocks

Pharmaceutical Preparations Industry

2nd out of 433 stocks

BMY stock logo

About Bristol-Myers Squibb Stock (NYSE:BMY)

The Bristol-Myers Squibb Company is a leading global biopharmaceutical company with a long and impressive history of innovating and developing medicines that improve the lives of patients around the world. Founded in 1887 when William McLaren Bristol and John Ripley Myers purchased the Clinton Pharmaceutical Company, the company was initially named Bristol, Myers and Company. Its first nationally recognized product, Sal Hepatica, was released in the 1890s.

Bristol Myers-Squibb offers chemically synthesized drugs and biologics administered through injections or infusions to patients. The company's pharmaceutical portfolio includes a large number of well-known products. BMS's primary research and development sites are in New Jersey, California, Spain, Massachusetts, New York, Belgium, Japan, India and Massachusetts. The company's products sell to wholesalers and distributors around the world.

Bristol Myers-Squibb has a robust pipeline of investigational medicines in its pipeline. In addition, the company has established strategic collaborations and partnerships with various companies, successfully launching new products. These partnerships and investments generate portions of the company's revenue. 

Bristol Myers-Squibb has acquired several companies over the years, including Medarex in 2009, ZymoGenetics in 2010, Inhibitex Inc. in 2012, Amylin Pharmaceuticals in 2012, iPierian in 2014, Flexus Biosciences in 2015, Cardioxyl in 2015, Padlock Therapeutics in 2016, Cormorant Pharmaceuticals in 2017, IFM Therapeutics in 2017, Celgene in 2019, Otezla in 2019, Forbius in 2020, MyoKardia in 2020 and Turning Point Therapeutics in 2022.

In 2005, the company divested individual consumer products and its subsequent consumer products businesses. In December 2014, the company received FDA approval for its cancer drug, Opdivo, used to treat skin cancers that do not respond to drug therapies. In 2019, the company divested its consumer health business, UPSA, to Taisho. 

The company has also faced several scandals, lawsuits and investigations over the years, the biggest of which is the ongoing $1 billion lawsuit from Guatemala for the company's role in a 1940s experiment that infected hundreds with syphilis. In 2001 BMS faced an accounting scandal that resulted in a restatement of revenues from 1999 to 2001. In 2002, BMS faced a lawsuit based on illegally maintaining a monopoly on Taxol, a chemotherapy medication. The former head of the pharma group and the ex-CFO were indicted for federal securities violations in 2005. In July of 2006, an FBI raid on the company's corporate offices revealed that the company took steps to delay the release of a generic version of one of its drugs.  

BMS began a significant restructuring in 2009, focusing on the pharmaceutical business and biologic products, productivity initiatives and cost-cutting. The U.S. attorney forced the company into oversight and appointed a monitor as part of a deferred prosecution agreement. Lou Schmukler joined Bristol-Myers Squibb in 2010 as global product development and design president. 

In 2013, Forbes magazine ranked the company as the drug company of the year. Dr. Giovanni Caforio took the reigns as CEO in 2015. In 2017, reports began to surface that activist investor Carl Icahn took a stake in the company, widely seen as a signal for a potential future takeover. 

As Bristol-Myers Squibb continues to experience success and growth, the company is committed to delivering innovative treatments to patients and staying ahead of the curve in the biopharmaceutical industry. With its focus on research and development and a long and rich history of delivering innovative medicines, BMS offers an excellent long-term investment opportunity.

BMY Stock Price History

BMY Stock News Headlines

Insider Trading is Good News for These Stocks
Insider Trading is Good News for These Stocks (BMY)
Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
Savvy stock investors often look for bargains using the Relative Strength Index (RSI). This technical tool evaluates a stock's performance over the last 14 days and assigns a value from 0 to 100.
Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore (BMY)
The sudden divergence has made clear some laggards who have ultra-low RSI readings that might just be too good to ignore. Here are 3 worth watching closely.
3 Blue-Chip Stocks to Buy at 52-Week Lows in May
Bristol-Myers Squibb (NYSE:BMY) Shares Down 0.7%
Pfizer to Cut Costs in Multi-Year Effort
See More Headlines
Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 5/1 Dividend
Last Earnings
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
19 Analysts


Net Income
$8.03 billion
Pretax Margin


Sales & Book Value

Annual Sales
$45.01 billion
Cash Flow
$12.23 per share
Book Value
$14.49 per share


Outstanding Shares
Free Float
Market Cap
$82.08 billion

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Christopher S. Boerner Ph.D.Dr. Christopher S. Boerner Ph.D. (Age 53)
    CEO & Chairman
    Comp: $3.14M
  • Mr. David V. ElkinsMr. David V. Elkins (Age 56)
    Executive VP & CFO
    Comp: $2.28M
  • Ms. Sandra Leung Esq. (Age 63)
    Executive VP & General Counsel
    Comp: $2.58M
  • Mr. Samit Hirawat M.D. (Age 55)
    Executive VP, Chief Medical Officer & Head of Development
    Comp: $2.62M
  • Mr. Greg Meyers (Age 51)
    Executive VP and Chief Digital & Technology Officer
  • Mr. Timothy Power
    VP & Head of Investor Relations
  • Ms. Kimberly M. Jablonski
    Chief Compliance & Ethics Officer
  • Ms. Ahn Amanda Poole (Age 49)
    Executive Vice President & Chief Human Resources Officer
  • Dr. Joseph J. Eiden Jr. (Age 75)
    Head of Medical Affairs
  • Mr. Adam Lenkowsky (Age 52)
    Executive VP, Chief Commercialization Officer & Head of U.S. Oncology

BMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Bristol-Myers Squibb stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last twelve months. There are currently 1 sell rating, 15 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.
View BMY analyst ratings
or view top-rated stocks.

What is Bristol-Myers Squibb's stock price target for 2024?

19 brokers have issued 1-year target prices for Bristol-Myers Squibb's stock. Their BMY share price targets range from $43.00 to $85.00. On average, they predict the company's stock price to reach $60.00 in the next year. This suggests a possible upside of 48.2% from the stock's current price.
View analysts price targets for BMY
or view top-rated stocks among Wall Street analysts.

How have BMY shares performed in 2024?

Bristol-Myers Squibb's stock was trading at $51.31 at the beginning of 2024. Since then, BMY shares have decreased by 21.1% and is now trading at $40.49.
View the best growth stocks for 2024 here

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 28,020,000 shares, a drop of 18.5% from the April 15th total of 34,360,000 shares. Based on an average daily volume of 15,430,000 shares, the short-interest ratio is presently 1.8 days. Approximately 1.4% of the company's stock are short sold.
View Bristol-Myers Squibb's Short Interest

When is Bristol-Myers Squibb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our BMY earnings forecast

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) released its quarterly earnings results on Thursday, April, 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts' consensus estimates of ($4.53) by $0.13. The biopharmaceutical company earned $11.87 billion during the quarter, compared to analysts' expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive trailing twelve-month return on equity of 8.83%. The business's quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the company earned $2.05 EPS.
Read the conference call transcript

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Friday, March 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.60 per share on Wednesday, May 1st. This represents a $2.40 annualized dividend and a yield of 5.93%. The ex-dividend date of this dividend is Thursday, April 4th.
Read our dividend analysis for BMY

Is Bristol-Myers Squibb a good dividend stock?

Bristol-Myers Squibb (NYSE:BMY) pays an annual dividend of $2.40 per share and currently has a dividend yield of 5.82%. BMY has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for BMY.

When did Bristol-Myers Squibb's stock split?

Bristol-Myers Squibb's stock split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were payable to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

How will Bristol-Myers Squibb's stock buyback program work?

Bristol-Myers Squibb announced that its Board of Directors has initiated a stock repurchase plan on Thursday, December 7th 2023, which authorizes the company to buyback $3,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 2.9% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY24 earnings guidance on Thursday, April, 25th. The company provided earnings per share guidance of $0.40-0.70 for the period, compared to the consensus earnings per share estimate of $0.65.

What is Giovanni Caforio's approval rating as Bristol-Myers Squibb's CEO?

659 employees have rated Bristol-Myers Squibb Chief Executive Officer Giovanni Caforio on Giovanni Caforio has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.18%), Capital International Investors (3.46%), Bank of New York Mellon Corp (0.82%), Price T Rowe Associates Inc. MD (0.62%), Pzena Investment Management LLC (0.61%) and Boston Partners (0.51%). Insiders that own company stock include Ann Powell, Autenried Paul Von, Christopher S Boerner, David V Elkins, Giovanni Caforio, Karen Murphy Santiago, Robert M Plenge, Rupert Vessey, Sandra Leung and Theodore R Samuels II.
View institutional ownership trends

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Bristol-Myers Squibb have any subsidiaries?
The following companies are subsidiares of Bristol-Myers Squibb: 1096271 B.C. ULC, 345 Park LLC, A.G. Medical Services P.A., AHI Investment LLC, AbVitro LLC, Abraxis BioScience Australia Pty Ltd., Abraxis BioScience Inc., Abraxis BioScience International Holding Company Inc., Abraxis BioScience LLC, Abraxis BioScience Puerto Rico LLC, Acetylon Pharmaceuticals Inc., Adnexus, Adnexus a Bristol-Myers Squibb R&D Company, Allard Labs Acquisition G.P., Amira Pharmaceuticals, Amira Pharmaceuticals Inc., Amylin Pharmaceuticals, Apothecon LLC, B-MS Generx Unlimited Company, BMS Benelux Holdings B.V., BMS Bermuda Nominees L.L.C., BMS Data Acquisition Company LLC, BMS Forex Company, BMS Holdings Sarl, BMS Holdings Spain S.L., BMS International Insurance Designated Activity Company, BMS Investco SAS, BMS Korea Holdings L.L.C., BMS Latin American Nominees L.L.C., BMS Luxembourg Partners L.L.C., BMS Omega Bermuda Holdings Finance Ltd., BMS Pharmaceutical Korea Limited, BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., BMS Real Estate LLC, BMS Spain Investments LLC, BMS Strategic Portfolio Investments Holdings Inc., Blisa Acquisition G.P., Bristol (Iran) S.A., Bristol Iran Private Company Limited, Bristol Laboratories Inc., Bristol Laboratories International S.A., Bristol Laboratories Medical Information Systems Inc., Bristol-Myers (Andes) L.L.C., Bristol-Myers (Private) Limited, Bristol-Myers Middle East S.A.L., Bristol-Myers Overseas Corporation, Bristol-Myers Squibb (China) Investment Co. Ltd., Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., Bristol-Myers Squibb (Israel) Ltd., Bristol-Myers Squibb (NZ) Limited, Bristol-Myers Squibb (Proprietary) Limited, Bristol-Myers Squibb (Shanghai) Trading Co. Ltd., Bristol-Myers Squibb (Singapore) Pte. Limited, Bristol-Myers Squibb (Taiwan) Ltd., Bristol-Myers Squibb (West Indies) Ltd., Bristol-Myers Squibb A.E., Bristol-Myers Squibb Aktiebolag, Bristol-Myers Squibb Argentina S. R. L., Bristol-Myers Squibb Australia Pty. Ltd., Bristol-Myers Squibb Axia Limited, Bristol-Myers Squibb B.V., Bristol-Myers Squibb Belgium S.A., Bristol-Myers Squibb Business Services Limited, Bristol-Myers Squibb Canada Co., Bristol-Myers Squibb Canada International Limited, Bristol-Myers Squibb Delta Company Limited, Bristol-Myers Squibb Denmark Filial of Bristol-Myers Squibb AB, Bristol-Myers Squibb EMEA Sarl, Bristol-Myers Squibb Egypt LLC, Bristol-Myers Squibb Epsilon Holdings Unlimited Company, Bristol-Myers Squibb Farmaceutica Ltda., Bristol-Myers Squibb Farmaceutica Portuguesa S.A., Bristol-Myers Squibb GesmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Bristol-Myers Squibb Holding Germany GmbH & Co. KG, Bristol-Myers Squibb Holdings 2002 Limited, Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH, Bristol-Myers Squibb Holdings Ireland Unlimited Company, Bristol-Myers Squibb Holdings Limited, Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company, Bristol-Myers Squibb Ilaclari Inc., Bristol-Myers Squibb India Pvt. Limited, Bristol-Myers Squibb International Company Unlimited Company, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Investco L.L.C., Bristol-Myers Squibb K.K., Bristol-Myers Squibb Kft., Bristol-Myers Squibb Luxembourg International S.C.A., Bristol-Myers Squibb Luxembourg S.a.r.l., Bristol-Myers Squibb MEA GmbH, Bristol-Myers Squibb Manufacturing Company, Bristol-Myers Squibb Marketing Services S.R.L., Bristol-Myers Squibb Middle East & Africa FZ-LLC, Bristol-Myers Squibb Norway Ltd., Bristol-Myers Squibb Nutricionales de Mexico S. de R.L. de C.V., Bristol-Myers Squibb Peru S.A., Bristol-Myers Squibb Pharma (HK) Ltd, Bristol-Myers Squibb Pharma (Thailand) Limited, Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma EEIG, Bristol-Myers Squibb Pharma Holding Company LLC, Bristol-Myers Squibb Pharma Ventures Corporation, Bristol-Myers Squibb Pharmaceuticals Limited, Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Bristol-Myers Squibb Polska Sp. z o.o., Bristol-Myers Squibb Products SA, Bristol-Myers Squibb Puerto Rico Inc., Bristol-Myers Squibb Puerto Rico/Sanofi Pharmaceutical Partnership Puerto Rico, Bristol-Myers Squibb Romania S.R.L., Bristol-Myers Squibb S.A.U., Bristol-Myers Squibb S.r.l., Bristol-Myers Squibb SA, Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Bristol-Myers Squibb Sarl, Bristol-Myers Squibb Service Ltd., Bristol-Myers Squibb Services Sp. z o.o., Bristol-Myers Squibb Spol. s r.o., Bristol-Myers Squibb Theta Finance Ltd., Bristol-Myers Squibb Trustees Limited, Bristol-Myers Squibb Verwaltungs GmbH, Bristol-Myers Squibb de Colombia S.A., Bristol-Myers Squibb de Costa Rica Sociedad Anonima, Bristol-Myers Squibb de Guatemala S.A., Bristol-Myers Squibb de Mexico S. de R.L. de C.V., Bristol-Myers Squibb/Astrazeneca EEIG, Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bristol-Myers de Venezuela S.C.A., CHT I LLC, CHT II LLC, CHT III LLC, CHT IV LLC, CR Finance Company LLC, Cardioxyl Pharmaceuticals, Cardioxyl Pharmaceuticals Inc., Celem LLC, Celem Ltd., Celgene, Celgene A.B., Celgene AS, Celgene Ab (Finland), Celgene Alpine Investment Co. II LLC, Celgene Alpine Investment Co. III LLC, Celgene Alpine Investment Co. LLC, Celgene ApS, Celgene B.V., Celgene BVBA, Celgene Brasil Produtos Farmacêuticos Ltda., Celgene CAR LLC, Celgene CAR Ltd., Celgene Chemicals Sarl, Celgene China Holdings LLC, Celgene Co., Celgene Corporation, Celgene Distribution B.V., Celgene EngMab GmbH, Celgene Europe B.V., Celgene Europe Limited, Celgene European Investment Company LLC, Celgene Financing Company LLC, Celgene Global Holdings Sarl, Celgene GmbH [Austria], Celgene GmbH [Germany], Celgene GmbH [Switzerland], Celgene Holdings East Corporation, Celgene Holdings II Sarl, Celgene Holdings III Sarl, Celgene Ilaç Pazarlama ve Ticaret Limited Şirketi, Celgene Inc., Celgene International Holdings Corporation, Celgene International II Sàrl, Celgene International III Sàrl, Celgene International Inc., Celgene International Sàrl, Celgene K.K., Celgene Kft., Celgene Limited [Hong Kong], Celgene Limited [Ireland], Celgene Limited [New Zealand], Celgene Limited [Taiwan], Celgene Limited [UK], Celgene Logistics Sàrl, Celgene Ltd, Celgene Luxembourg Sarl, Celgene Management Sàrl, Celgene NJ Investment Co, Celgene Netherlands B.V., Celgene Netherlands Investment B.V., Celgene Pharmaceutical (Shanghai) Co. Ltd., Celgene Pte. Ltd., Celgene Pty Ltd, Celgene Puerto Rico Distribution LLC, Celgene Quanticel Research Inc, Celgene R&D Sàrl, Celgene RIVOT LLC, Celgene RIVOT Ltd., Celgene RIVOT SRL, Celgene Receptos Limited, Celgene Receptos Sàrl, Celgene Research Incubator At Summit West LLC, Celgene Research S.L.U., Celgene Research and Development Company LLC, Celgene Research and Development I ULC, Celgene Research and Development II LLC, Celgene Research and Investment Company II LLC, Celgene S. de R.L. de C.V., Celgene S.L.U., Celgene S.R.L., Celgene SAS, Celgene Sarl AU, Celgene Sdn Bhd, Celgene Services Sàrl, Celgene Sociedade Unipessoal Lda, Celgene Sp. Z.o.o., Celgene Sro [Czech Republic], Celgene Summit Investment Co, Celgene Switzerland Holding Sarl, Celgene Switzerland II LLC, Celgene Switzerland Investment Sarl, Celgene Switzerland LLC, Celgene Switzerland Sarl, Celgene Tri A Holdings Ltd., Celgene Tri Sarl, Celgene UK Distribution Limited, Celgene UK Holdings Limited, Celgene UK Manufacturing II Limited, Celgene UK Manufacturing III Limited, Celgene UK Manufacturing Limited, Celgene d.o.o., Celgene sro [Slovakia], Celmed LLC, Celmed Ltd., ConvaTec Divestiture, Cormorant Pharmaceuticals, Cormorant Pharmaceuticals AB, Crosp Ltd., Delinia Inc., Deuteria Pharmaceuticals Inc., DuPont Pharmaceuticals, E. R. Squibb & Sons Inter-American Corporation, E. R. Squibb & Sons L.L.C., E. R. Squibb & Sons Limited, EWI Corporation, EngMab Sarl, F-star Alpha, FermaVir Pharmaceuticals L.L.C., FermaVir Research L.L.C., Flexus Biosciences, Flexus Biosciences Inc., Forbius, Galecto Biotech, GenPharm International L.L.C., Gloucester Pharmaceuticals LLC, Grove Insurance Company Ltd., Heyden Farmaceutica Portuguesa Limitada, IFM Therapeutics, Impact Biomedicines Inc., Inhibitex, Inhibitex L.L.C., Innate Tumor Immunity Inc., JuMP Holdings LLC, Juno Therapeutics GmbH, Juno Therapeutics Inc., Kosan Biosciences, Kosan Biosciences Incorporated, Linson Investments Limited, Mead Johnson (Manufacturing) Jamaica Limited, Mead Johnson Jamaica Ltd., Medarex, Morris Avenue Investment II LLC, Morris Avenue Investment LLC, MyoKardia, O.o.o. Bristol-Myers Squibb, Oy Bristol-Myers Squibb (Finland) AB, Padlock Therapeutics, Padlock Therapeutics Inc., Pharmion LLC, Princeton Pharmaceutical Products Inc., Receptos LLC, Receptos Services LLC, RedoxTherapies Inc., Route 22 Real Estate Holding Corporation, SPV A Holdings ULC, Seamair Insurance DAC, Signal Pharmaceuticals LLC, Sino-American Shanghai Squibb Pharmaceuticals Limited, Societe Francaise de Complements Alimentaires(S.O.F.C.A.), Squibb Middle East S.A., Summit West Celgene LLC, Swords Laboratories, VentiRx Pharmaceuticals Inc., Westwood-Intrafin SA, Westwood-Squibb Pharmaceuticals Inc., X-Body Inc., ZymoGenetics, ZymoGenetics Inc., ZymoGenetics LLC, ZymoGenetics Paymaster LLC, iPierian, and iPierian Inc..
Read More
This page (NYSE:BMY) was last updated on 5/29/2024 by Staff

From Our Partners